Author Archives: Antigone Barton

Gilead, sofosbuvir, and hepatitis C . . . We’re reading about the high cost of living

By on .

The Treatment Action Group’s 2014 Pipeline Report released in conjunction with the 20th International AIDS Conference last week devotes three sections to the outlook for better and more accessible treatment for hepatitis C, examining the promise of new direct acting antiviral treatments, starting with sofosbuvir (marketed by Gilead pharmaceutical company as Sovaldi) being eclipsed by […]

World Hepatitis Day: Sub-Saharan Africa sees progress, but persisting risks for HBV, HBC transfusion-transmitted infections, CDC reports

By on .

More countries were screening donated blood for hepatitis B and hepatitis C across sub-Saharan Africa by 2011, than 10 years earlier but prevention of transfusion-transmitted disease remains challenged across the region, a report from the United States Center for Disease Control and Prevention released last week shows. The report, in the CDC’s Morbidity and Mortality […]

A look at AIDS 2014: Stigma and discrimination pose barriers to accessing health services

By on .

Science Speaks covered AIDS 2014 with live coverage and guest posts and is continuing this week with insights on issues raised during the week. The following post is by Laura Nyblade, of Health Policy Project, RTI International MELBOURNE, AUSTRALIA —Nearly every plenary speaker at the International AIDS Conference last week, from political leaders to scientists […]

In the wake of loss, we’re reading about six lives and legacies that moved the world closer to justice, equity and global health

By on .

Among the 298 people whose deaths in the crash MH17 last week left the world saddened and diminished, the loss of the six who were on their way to the 20th International AIDS Conference in Melbourne left a community that was founded on loss and driven by the value of all lives reflecting on what […]

AIDS 2014: Financing the new global HIV treatment vision – advocacy and economics

By on .

The following is a guest post from Arin Dutta, Senior Economist, and Ron MacInnis, Deputy Director for HIV, Health Policy Project, Futures Group   MELBOURNE, AUSTRALIA – Here at the 2014 International AIDS Conference, UNAIDS has put forward a vision for global HIV treatment – “ 90-90-90 by 2020 “ – 90 percent of those […]

PaMZ TB drug regimen: Cheaper, simpler, safer and with effectiveness “significantly greater” than standard regimen, researchers say

By on .

An analysis of eight-week data from a clinical trial of a tuberculosis treatment regimen shows the promise of curing the disease in a shorter period of time, at a fraction of the current cost, and with no need for painful injections, researchers at the International AIDS Conference in Melbourne, Australia said Monday. They were announcing […]

AIDS 2014: When HIV Research and Data Collection Is at Odds with “Do No Harm”

By on .

The following is a guest post from Health Policy Project Senior Policy Advisor Anita Datar and Health Policy Project Ron MacInnis, of the Futures Group. By Anita Datar, Senior Policy Advisor, and Ron MacInnis, Deputy Director for HIV, Health Policy Project, Futures Group MELBOURNE, AUSTRALIA —Using maps to understand spatial patterns in disease epidemics is […]

The Voice of Public Health Leadership Globally: Marginalized

By on .

The following is a guest post by Ron MacInnis, Deputy Director for HIV. By Ron MacInnis WASHINGTON, DC — My visit to Uganda last month – and meetings with many dedicated health professionals and HIV advocates – left me with concerns about the direction of the country’s HIV response and about the continued impact of […]

Disabilities and HIV in Zambia, faith-based opportunities to provide bridges to services, and Malawi steps up . . . We’re reading reports on gaps and how to fill them

By on .

“We Are Also Dying of AIDS” – This report from Human Rights Watch on Barriers to HIV Services and Treatment for Persons with Disabilities in Zambia is dedicated to the late Winstone Zulu, the Zambian activist  who pushed for HIV and TB responses to reach people marginalized by poverty, cultural bias, discriminatory laws, and institutionalized […]